Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;6(2):Article 18.
doi: 10.2202/1557-4679.1212.

When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data

Affiliations

When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data

Lauren E Cain et al. Int J Biostat. 2010.

Abstract

Dynamic treatment regimes are the type of regime most commonly used in clinical practice. For example, physicians may initiate combined antiretroviral therapy the first time an individual's recorded CD4 cell count drops below either 500 cells/mm3 or 350 cells/mm3. This paper describes an approach for using observational data to emulate randomized clinical trials that compare dynamic regimes of the form “initiate treatment within a certain time period of some time-varying covariate first crossing a particular threshold." We applied this method to data from the French Hospital database on HIV (FHDH-ANRS CO4), an observational study of HIV-infected patients, in order to compare dynamic regimes of the form "initiate treatment within m months after the recorded CD4 cell count first drops below x cells/mm3" where x takes values from 200 to 500 in increments of 10 and m takes values 0 or 3. We describe the method in the context of this example and discuss some complications that arise in emulating a randomized experiment using observational data.

PubMed Disclaimer

References

    1. Ancelle-Park R, Klein JP, Stroobant A, et al. Expanded European AIDS case definition. The Lancet. 1993;341:441. doi: 10.1016/0140-6736(93)93040-8. - DOI - PubMed
    1. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. The Lancet. 1998;351:543–549. doi: 10.1016/S0140-6736(97)04161-5. - DOI - PubMed
    1. CDC 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report. 1992;41:1–19. - PubMed
    1. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. American Journal of Epidemiology. 2008;168:656–664. doi: 10.1093/aje/kwn164. - DOI - PMC - PubMed
    1. Cole SR, Hernán MA, Robins JM, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. American Journal of Epidemiology. 2003;158:687–694. doi: 10.1093/aje/kwg206. - DOI - PubMed

Publication types

Substances